<code id='79FB01E2A3'></code><style id='79FB01E2A3'></style>
    • <acronym id='79FB01E2A3'></acronym>
      <center id='79FB01E2A3'><center id='79FB01E2A3'><tfoot id='79FB01E2A3'></tfoot></center><abbr id='79FB01E2A3'><dir id='79FB01E2A3'><tfoot id='79FB01E2A3'></tfoot><noframes id='79FB01E2A3'>

    • <optgroup id='79FB01E2A3'><strike id='79FB01E2A3'><sup id='79FB01E2A3'></sup></strike><code id='79FB01E2A3'></code></optgroup>
        1. <b id='79FB01E2A3'><label id='79FB01E2A3'><select id='79FB01E2A3'><dt id='79FB01E2A3'><span id='79FB01E2A3'></span></dt></select></label></b><u id='79FB01E2A3'></u>
          <i id='79FB01E2A3'><strike id='79FB01E2A3'><tt id='79FB01E2A3'><pre id='79FB01E2A3'></pre></tt></strike></i>

          fashion

          fashion

          author:entertainment    Page View:2445
          Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed. Joe Raedle/Getty Images

          Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed, per reports from Bloomberg.

          Experts largely hailed the rumored sale as a good buy, citing the management of chronic conditions in the Medicare Advantage population through primary care, ChenMed’s specialty, as an area with huge innovation and cost savings over the last 10 years.

          advertisement

          “If you’re going to purchase primary care in the senior space, there’s no one better than ChenMed. The only other one that might be better or equivalent would be Oak Street, but they were just purchased,” said Jon Kaplan, a senior partner at BCG. “In the world of great primary care practices to buy, in my top two are Oak Street and ChenMed, and one of them’s available, one’s not.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Key Senate panel to consider PBM, drug pricing reform package
          Key Senate panel to consider PBM, drug pricing reform package

          Sens.RonWydenandMikeCrapointroducedamentalhealth,PBMreformandsubstanceusepolicypackage.DrewAngerer/G

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          After Sarepta trial failure, Duchenne families brace for more debate

          KristofferTripplaar/SipaviaAPTohearSareptaCEODougIngramtellit,theresultsMondayafternoonfromalargetri